Medicare Is Denying More Claims Than Ever -- Here's How to Fight Back

4.1 million prior-authorization requests were fully or partially denied in Medicare Advantage in 2024 (KFF). Appeals are often successful—most appeals result in full or partial overturns—so beneficiaries should act quickly (usually 120 days for Original Medicare), involve their doctor, and follow the prescribed steps (Redetermination CMS-20027, Reconsideration CMS-20033, ALJ hearing OMHA-100). Free assistance is available via the Medicare Rights Center (800-333-4114) and state SHIP programs (877-839-2675).

Analysis

Claims-denial friction is a persistent, high-friction workflow that creates a multi-year demand stream for automated decisioning, document ingestion, and clinician-review orchestration. That demand maps cleanly to GPU-accelerated inference (large models to interpret records) and to cloud-hosted orchestration platforms; a conservative scenario where 1–3% of US clinical review workloads convert to GPU-based AI within 12–24 months implies a measurable bump to datacenter utilization that favors incumbents with dominant inference stacks.

NVDA is the direct architectural winner in that scenario — accelerating adoption of model-based medical necessity review raises marginal GPU cycle demand and shortens customer procurement cycles for third-party vendors. Intel is a second-order play: if it executes on a differentiated inference roadmap for on-prem/edge reviewers it could capture non-GPU share, but the window to prove that to large payers/providers is narrow (6–18 months) and execution-sensitive.

Regulatory and policy catalysts dominate timing risk: any federal/state moves to standardize prior-authorization rules, mandate one-touch electronic prior auth, or cap appeal outcomes would compress the need for complex ML review and re-route spend to compliance tooling instead. Conversely, persistent ALJ/backlog-driven litigation and payer outsourcing trends would extend vendor TAM for 2–4 years. The clearest behavioral catalyst to watch is payer 10-Q/earnings language around “automation/AI spend” and provider IT budgets in the next two quarterly reporting cycles.

Key Decisions for Investors

• Long NVDA via 9–12 month call spread (size 1–2% notional): buy near-the-money calls and sell 20–30% higher strikes to finance premium. Rationale: capture incremental datacenter/GPU demand from automated claims/appeals workflows. Exit/trim if NVDA reports datacenter revenue guidance miss >4% or if payer tech spend commentary turns negative. Target 2–4x premium return.
• Relative pair: long NVDA / short INTC (6–18 month horizon, market-neutral delta sizing ~0.6x): go long NVDA equity or calls and short INTC to isolate GPU vs CPU inference secular divergence. Trim if the NVDA/INTC spread tightens < -15% from entry or if Intel announces a materially credible inference product win in healthcare.
• Opportunistic long NDAQ (12 months): small weight (0.5–1%) ahead of expected consolidation and capital raises in digital-health/adjudication SaaS — benefits from listing/ancillary services. Hedge with a 6–9 month put if regulatory headlines mandate significant prior-auth reform that could depress new issuance. Risk/reward skew: modest upside from fee capture vs regulatory policy risk.